Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Prempro DTC Campaign Touts Lowest Approved Dose Of Hormone Therapy

Executive Summary

Wyeth's direct-to-consumer advertising campaign for Prempro highlights the hormone replacement therapy's lowest dose approved by FDA

You may also be interested in...



Beyond Hormone Therapy: Signs Of Life In Pipeline For Menopausal Women

Conditions associated with menopause represent a huge market, yet the R&D pipeline has long been slim, despite the well-known drawbacks of marketed hormone replacement therapies. But new approaches with a tissue-selective estrogenic effect are emerging: Shionogi’s Osphena for menopause-related sexual dysfunction broke the long drought in NME approvals, and Pfizer’s broad NDA for bazedoxifene/conjugated estrogens is under review. Emerging companies like EndoCeutics are exploring new hormonal approaches.

Wyeth Using Unbranded Ads To Stimulate Premarin, Prempro Growth

Wyeth's latest direct-to-consumer advertising campaign for its estrogen franchise suggests emerging use of unbranded ads for leading products in mature markets

Wyeth Using Unbranded Ads To Stimulate Premarin, Prempro Growth

Wyeth's latest direct-to-consumer advertising campaign for its estrogen franchise suggests emerging use of unbranded ads for leading products in mature markets

Related Content

Topics

UsernamePublicRestriction

Register

ID005817

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel